Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study of REGN7041 (Anti-CD3 Monoclonal Antibody) in Participants With Active Noninfectious Uveitis Affecting the Posterior Segment

NCT07218770 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT07218770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07218770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study of REGN7041 (Anti-CD3 Monoclonal Antibody) in Participants With Active Noninfectious Uveitis Affecting the Posterior Segment
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 1/2
Overall status
Terminated
Start date
December 17, 2025
Completion date
July 21, 2026
Enrollment
1 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

active noninfectious uveitis affecting the posterior segment